Birzeit Pharmaceutical Co (XPAE:BPC) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAE:BPC Birzeit Pharmaceutical Co XPAE:BPC
91 GF Score
Price $3.65
GF Value $4.59
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Birzeit Pharmaceutical Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Birzeit Pharmaceutical Co Quality Rank Related Terms

XPAE:BPC
91GF Score
Birzeit Pharmaceutical Co XPAE:BPC
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?

Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued. The current stock price of $3.65 is trading 20.5% below its estimated GF Value™ of $4.59. GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for XPAE:BPC:

  • Quality Rank:
  • GF Value™: $4.59 vs. price of $3.65 (20.5% below fair value)
  • GF Score™: 91/100 with 3 warning signs

No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Birzeit Pharmaceutical Co Business Description

Address 20 Shatella Street, Betunia Industrial Area, Ramallah, PSE
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score

Get the complete analysis for XPAE:BPC

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.65
Price
$4.59
GF Value